A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to ensure adequate treatment dosage for further study. Meanwhile, the study also evaluate Pharmacokinetics of Gentuximab Injection at different dosage in combination with Paclitaxel.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GeneScience Pharmaceuticals Co., Ltd.
• Collaborators: First Hospital of Jilin University; Fujian Tumor Hospital; Shanghai East Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Sir Run Run Shaw Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; The Affiliated Tumor Hospital of Harbin Medical University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital, Zhejiang University School of Medicine; The First Hospital of Jilin University; The Sixth Hospital of Sun Yat-sen University; Tongji Hospital; Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology; Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• The subject can understand the process and methods of the study, complete the study in accordance with the protocol and is willing to sign a written informed consent.

• Male or female. aged between 18 and 75 years

• Histopathologically confirmed advanced advanced gastric or gastroesophageal junction cancer, and Documented progression during first-line fluoropyrimidine- and platinum- containing chemotherapy, or during the 3 months following the last cycle of such chemotherapy (or during the 6 months following the last dose of adjuvant therapy or new adjuvant therapy containing fluoropyrimidine and platinium).

• At least one Measurable lesion.

• ECOG Performance status (PS) score, 0-1 level.

• A life expectancy of >3 months.

• Adequate hematologic function, as defined by: Absolute neutrophil count (ANC) ≥1.5×109/L; hemoglobin concentration ≥90g/L (allowing blood transfusion); and platelet count ≥80×109/L.

• Adequate hepatic function, as defined by: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN (liver metastases patients ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN).

• Adequate renal function, as defined by: serum creatinine level≤ 1.5 × ULN, or creatinine clearance ≥ 50ml / min when serum creatinine level> 1.5 × ULN.

• Adequate coagulation function, as defined by: International normalized ratio (INR) ≤1.5× ULN, activated partial thromboplastin time (aPTT) ≤1.5 x ULN.

• 24-hour urine protein quantitation is <1g（24-hour urine protein quantitative test should be performed when urine protein ≥1+ is found during screening visit）.

• Subjects (male and female) who have fertility must agree to use reliable contraceptive methods during the trial and in 3 months after the last administration. Female subjects in childbearing age must be negative for blood pregnancy test prior to enrollment.

Exclusion Criteria:

• Previously administrated with anti-angiogenic drugs or paclitaxel.

• Systematic anti-tumor therapy (non-anti-angiogenic drugs or paclitaxel) such as chemotherapy, radiotherapy, macromolecular targeted therapy, immunotherapy, endocrine therapy, etc. within 4 weeks before the first dose of investigational drug, except for the following: nitrourea or mitomycin C is within 6 weeks before the first dose, oral fluorouracil and small molecule targeted drugs are within 2 weeks or 5 half-life of the drug(whichever is longer) before the first dose，Chinese medicine with anti-cancer indications is within 2 weeks before the first dose.

• Has participated in a clinical study of a non-approved experimental agent within 4 weeks prior to screening visit.

• Has undergone major surgery within 4 weeks before screening visit (not including needle biopsy)， or would undergo planned surgery during the study.

• Subject with positive HCV-Ab, Anti-HIV or TP-Ab, or positive HBS-Ag with copies of HBV DNA > ULN.

• Patients with previously confirmed malignant tumors.

• History of arterial thrombosis or deep vein thrombosis within 6 months prior to screening, or a bleeding event no less than Grade level 3 within 2 months prior to screening， or the investigator determines that there is a risk of bleeding.

• History of severe cardiovascular and cerebrovascular diseases.

• Subjects with confirmed brain tumor metastases，but subjects in steady situation can be enrolled.

• Active bleeding confirmed by gastroscopy when fecal occult blood positive (only subjects with primary lesions not removed need to do fecal occult blood test.

• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 12 months before screening visit.

• Thoracic，abdominal or pericardial effusion that cannot be controlled by repeated drainage or with obvious symptoms.

• Has a nonhealing wound, serious ulcer, or unrecovered bone fracture.

• Active infections requiring systemic treatment, including but not limited to active tuberculosis.

• Using anticoagulation and antiplatelet drugs.

• Female subjects who is pregnant (confirmed by urine or serum pregnancy test) or lactating.

• Has a known serious allergy reaction to recombination monoclonal antibody (MAb) drug, ,or infusion reaction.

• Has known alcohol or drug dependency.